Anemia, Diamond-Blackfan clinical trials
The registry lists 56 studies for Anemia, Diamond-Blackfan across more than 10 countries. 10 are recruiting or about to start. 18 of them are mainly about Anemia, Diamond-Blackfan (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Anemia, Diamond-Blackfan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Masonic Cancer Center, University of Minnesota (4) · St. Jude Children's Research Hospital (3) · Bellicum Pharmaceuticals (3) · Paul Szabolcs (3) · Northwell Health (3) · UCSF Benioff Children's Hospital Oakland (2)
What is being tested here
Drugs under test in Anemia, Diamond-Blackfan studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Fludarabine | 2 | 2 | 9 |
| Alemtuzumab | 2 | 1 | 4 |
| Hydroxyurea | 2 | 0 | 2 |
| Thiotepa | 2 | 0 | 2 |
| Melphalan | 1 | 0 | 3 |
| Rituximab | 1 | 0 | 2 |
| Deferasirox | 0 | 2 | 6 |
| Busulfan | 0 | 2 | 5 |
| Fludarabine phosphate | 0 | 1 | 5 |
| Cyclophosphamide | 0 | 1 | 3 |
Drug classes tested here Alkylating agents 2 open · Antimetabolites 2 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 4
- Nov 2026Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT · Paul Szabolcs
- Dec 2026AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion · Mitchell Cairo
- Feb 2027French National Registry of Bone Marrow Failures · Assistance Publique - Hôpitaux de Paris
- Apr 2027Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia · Apriligen, Inc.
Who these studies take
Of the 10 Anemia, Diamond-Blackfan studies recruiting now, 3 (30%) set no upper age limit and 6 (60%) stop at 75 or younger. 10 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (10%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 10 (100%) | 10 (100%) |
| 18 | 10 (100%) | 10 (100%) |
| 30 | 9 (90%) | 9 (90%) |
| 40 | 7 (70%) | 7 (70%) |
| 50 | 6 (60%) | 6 (60%) |
| 65 | 4 (40%) | 4 (40%) |
| 75 | 4 (40%) | 4 (40%) |
| 85 | 4 (40%) | 4 (40%) |
Across all 56 studies, recruiting or not: 63% stop at 75 or younger and 57% at 65; 93% take children; 0% are for women only and 0% for men only; 5% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 56. Browse all 56 → or search them.
- Cancer in Inherited Bone Marrow Failure SyndromesRecruitingNCT000272741 country
- Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)RecruitingNCT071861791 country
- AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell DepletionRecruitingNCT04099966Phase 21 country
- T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other AnemiasRecruitingNCT03653338Phase 1/21 country
- Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan AnemiaRecruitingNCT07476183Phase 11 country
- Familial Investigations of Childhood Cancer PredispositionRecruitingNCT030502681 country
- Investigation of the Genetics of Hematologic DiseasesRecruitingNCT027206791 country
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICRecruitingNCT045283551 country
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 21 country
- French National Registry of Bone Marrow FailuresRecruitingNCT047817901 country
- Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)CompletedNCT04965597Phase 21 country
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable1 country
- CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell TransplantationActive, not recruitingNCT01966367Phase 1/21 country
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerTerminatedNCT03333486Phase 21 country
- Treatment of Refractory Diamond-Blackfan Anemia With EltrombopagCompletedNCT04269889Phase 1/21 country
- Hematopoietic Stem Cell Transplant for High Risk HemoglobinopathiesTerminatedNCT02179359Not applicable1 country
- CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell TransplantActive, not recruitingNCT02061800Phase 1/21 country
- Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant DiseasesTerminatedNCT02231710Phase 11 country
- Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell TransplantTerminatedNCT02065869Phase 1/22 countries
- Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedNCT03733249Phase 1/21 country
- Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationCompletedNCT03513328Phase 1/21 country
- Safety and Efficacy Study of Sotatercept in Adults With Transfusion Dependent Diamond Blackfan AnemiaTerminatedNCT01464164Phase 1/21 country
- Phase I/II Pilot Study of Mixed Chimerism to Treat HemoglobinopathiesWithdrawnNCT01419704Phase 1/21 country
- The Use of Trifluoperazine in Transfusion Dependent DBATerminatedNCT03966053Phase 1/21 country
- Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan AnemiaCompletedNCT01362595Phase 1/21 country
- Human Placental-Derived Stem Cell TransplantationCompletedNCT01586455Phase 11 country
- Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited DisordersCompletedNCT00919503Phase 21 country
- A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow FailureTerminatedNCT00001962Phase 21 country
- Multi-Center Study of Iron Overload: Pilot StudyCompletedNCT011147763 countries
- Multi-Center Study of Iron Overload: Survey Study (MCSIO)CompletedNCT019135483 countries
- Stem Cell Transplant for HemoglobinopathyCompletedNCT00176852Phase 2/31 country
- A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron OverloadCompletedNCT00171821Phase 323 countries
- Bone Marrow Transplant With Abatacept for Non-Malignant DiseasesCompletedNCT01917708Phase 11 country
- Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 21 country
- Rituximab to Treat Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan AnemiaCompletedNCT00229619Phase 21 country
- Allo-HCT MUD for Non-malignant Red Blood Cell (RBC) Disorders: Sickle Cell, Thal, and DBA: Reduced Intensity Conditioning, Co-tx MSCsCompletedNCT00957931Phase 21 country
- Stem Cell Transplant for Bone Marrow Failure SyndromesCompletedNCT00176878Phase 2/31 country
- Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerTerminatedNCT00290628Not applicable1 country
- Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic DisordersCompletedNCT00301834Phase 21 country
- Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 21 country
- Alefacept and Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT01319851Not applicable1 country
- Partially Matched Stem Cell Transplantation for Patients With Refractory Severe Aplastic Anemia or Refractory CytopeniasCompletedNCT00244010Not applicable1 country
- Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood CellsTerminatedNCT02512679Phase 2
- Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron OverloadCompletedNCT00673608Phase 41 country
- A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe ToxicityCompletedNCT01044186Phase 23 countries
- L-leucine in Diamond Blackfan Anemia PatientsStatus unknownNCT02386267Phase 21 country
- Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 211 countries
- Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant DisordersCompletedNCT00744692Phase 11 country
- Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionCompletedNCT00305708Phase 1/21 country